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Edited by Vladimir SkulachevAbstract We investigate here the anti-angiogenic properties of
the synthetic compound myo-inositol trispyrophosphate (ITPP).
By increasing oxy-haemoglobin dissociation, ITPP has the
potential to counteract the eﬀects of hypoxia, a critical regulator
of angiogenesis and cancer progression. ITPP inhibited angio-
genesis of the chorioallantoic membrane (CAM), as analyzed
with an original program dedicated to automated quantiﬁcation
of angiogenesis in this model. ITPP also markedly reduced
tumor progression and angiogenesis in an experimental model
of U87 glioma cell nodules grafted onto the CAM. These results
point out the potential of ITPP for the development of a new
class of anti-angiogenic and anti-cancer compounds.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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quantiﬁcation1. Introduction
Angiogenesis, the main process of blood vessel formation, is
a hallmark of tumor progression [1], and anti-angiogenic com-
pounds are extensively studied for anti-cancer therapy [2].
However, angiogenesis involves complex regulatory pathways,
and compounds that are currently used in clinical trials, nota-
bly blockers of vascular growth factors and inhibitors of their
tyrosine kinase receptors, have limited eﬃcacy and exert someAbbreviations: CAM, chorioallantoic membrane; FOV, ﬁrst order ve-
ssel; IP6, inositol hexakisphosphate; ITPP, inositol trispyrophosphate;
pO2, partial oxygen pressure; SOV, second order vessel; VBR, vessel/
background ratio
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doi:10.1016/j.febslet.2007.01.079secondary eﬀects [3]. Therefore, new strategies are required to
sharpen and increase the eﬃciency of anti-angiogenic therapy.
Myo-inositol trispyrophosphate (ITPP) is a synthetic com-
pound derived from myo-inositol hexakisphosphate (IP6), a
natural molecule ubiquitously produced in mammalian cells
and previously reported for antioxidant [4] and anticancer [5]
properties. Unlike IP6, ITPP, which bears lower negative
charge, is soluble in both aqueous and lower polarity media
[6]. It is thus able to cross the red blood cell (RBC) membrane
and act as an allosteric eﬀector, increasing the oxygen release
from free haemoglobin as well as from whole blood [7]. In con-
trast, IP6 must be introduced into the RBC by physical meth-
ods in order to increase their oxygen release [8].
It was hypothesized that ITPP, by increasing the partial
pressure of oxygen (pO2) in hypoxic tissues, may act as an
anti-angiogenic compound. Indeed, pO2 is a crucial regulator
of angiogenesis: hypoxia is a major activator of blood vessel
formation [9,10], while hyperoxia has opposite eﬀects [10].
Human microvascular endothelial cells submitted to hypoxia
in the presence of human red blood cells loaded with ITPP
do not form capillary tube-like structures and do not express
HIF-1 [11]. In this report, we show that ITPP triggers defects
in the vascular network of the chick chorioallantoic membrane
(CAM) in ovo, consistent with an anti-angiogenic eﬀect during
physiological angiogenesis. To describe quantitatively the ef-
fects observed, we developed a new program that allows auto-
mated quantiﬁcation of several vascular network parameters
on angiographic images of the CAM. This original program
should prove useful for analysis of pro- or anti-angiogenesis
in the model of the CAM as it allows accurate, quick and easy
quantiﬁcation on large series of images. Finally, we report the
ability of ITPP to inhibit tumor growth and angiogenesis in an
experimental model of human glioma grafted onto the CAM.2. Materials and methods
Myo-inositol trispyrophosphate (ITPP) was prepared from myo-ino-
sitol hexakisphosphate (IP6) as previously described [7,11].
2.1. Chick embryos and cells
Fertilized eggs from White Leghorn chickens were obtained from a
commercial breeder (Haas, Kalten House, France). U87 human glioma
cells (American Type Culture Collection) were maintained in modiﬁed
E-MEM (LGC Promochem, France) with 10% FBS.blished by Elsevier B.V. All rights reserved.
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The chorioallantoic membrane (CAM) assay was adapted from Cel-
erier et al. [12]. At embryonic day 8 (E8), each CAM received two sil-
icon rings (10 mm-ID) laid onto two areas looking alike for their
vascularization. Twenty-ﬁve microliters of ITPP hexasodium salt
0.1 M [7] were applied on the ﬁrst ring, and 25 ll of vehicle (0.15 M
NaCl + 2.5 mM CaCl2) on the second one. After 24 h treatment,
CAM were either analyzed on angiographic pictures after i.v. injection
of FITC-dextran (see details in [13]), or collected for molecular histo-
logy.Fig. 1. Automated quantiﬁcation. (A) Computed analysis of CAM
vasculature, allowing, from an angiographic image (inset 1), the
quantiﬁcation of ﬁrst order vessels (FOV, inset 2), second order vessels
(SOV, inset 3) Bifurcations (Bif, inset 4) and vessel/background ratio
(VBR, inset 5) parameters, revealed in purple (for details, see Section
2). (B) Plots of computed measurements for the FOV parameter
against manual measurements of a ﬁrst observer (obs. 1). As a
comparison, plots of manual measurements of two other observers
(obs. 2 and obs. 3) against obs. 1 are shown. The equations of the
regression curves obtained for the diﬀerent plots as well as their
correlation scores (R2) are indicated. Scale bar: 400 lm.2.3. Quantiﬁcation of vascular parameters of the CAM
Quantiﬁcation was carried out on 1.8·-magniﬁed angiographic
images. Automated quantiﬁcation was performed as follows:
(A) Vessel segmentation. After normalizing the dynamic range of
the images, a preﬁltering step was applied to remove the capil-
lary bed (morphological closing by reconstruction, dynamic ﬁl-
tering [14] and volume leveling [15]). Then, the following
threshold scheme was applied: (1) A ﬁrst (high) threshold was
applied on the preﬁltered image in order to segment the bright
(thick) vessels. (2) The small vessels were extracted from the pre-
ﬁltered image by means of the top-hat transformation [14],
smoothed in their main direction with a Gaussian proﬁle ﬁlter
[16], and segmented with a second (low) threshold. These results
were combined resulting in a binary image representing the ves-
sels.
(B) Finding the extremities. Extremities of a binary set coincide with
the local maxima of its geodesic distance map [17,18]. However,
parasite maxima may exist due to (1) border irregularities and (2)
loops in the segmentation result. These two problems have been
overcome by (1) removing all local maxima with low dynamic
[14] and (2) carrying along a label image while constructing the
geodesic distance map, allowing the identiﬁcation of bifurca-
tions, and therewith the identiﬁcation of the parasite maxima
[18]. This method has been implemented eﬃciently using
FIFO-structures (queues). By the end of this procedure, all end-
points of the vascular tree were obtained, which coincided with
the ﬁrst order vessels [19].
(C) Calculation of a clean skeleton. The classical skeleton (set of one
pixel wide lines) of the vascular tree was calculated. From this
skeleton, we removed all branches with endpoints not coinciding
with the ones calculated in section 2.
(D) Calculation of parameters. From the segmentation result (A)
the ratio of the number of vascular pixels to the number of
non vascular pixels (VBR, vessel background ratio) was calcu-
lated, reﬂecting the vascular density. Alternatively, this mea-
sure can be calculated for small vessels only (SVBR), in
order to avoid the bias induced by large vessels. The extremities
(B) gave the number of ﬁrst order vessels (FOV). With the
skeleton (C) the number of bifurcations (three outgoing
branches), the number of crossings (four or more outgoing
branches), the number of second order vessels (SOV) [19], and
the length distribution and total length of the vascular tree were
calculated.
2.4. Reliability of the automated quantiﬁcation
Results obtained by manual observation by three diﬀerent observers
were compared to those of automated quantiﬁcation. For this compar-
ison, which was made on nine CAMs of a single experiment, the FOV
parameter was investigated. Plotting the computed data against those
of each observer revealed linear regression curves with scores (R2) of
0.74 ± 0.02 (Fig. 1B). As well, inter-observer comparisons also led to
linear curves with R2 of 0.82 ± 0.03 (Fig. 1B). Equations of the regres-
sion curves are in Fig. 1B.2.5. Experimental glioma assay
Experimental human glioma assays were performed on the CAM as
described by Hagedorn et al. [20]: at E10, a silicon ring was laid onto
the CAM, and 3–5 million U87 human glioma cells in 20 ll of medium
were deposited after gentle laceration of surface. At E12, embryos
bearing size-matching tumors were treated until E14 with 25 ll per
day of either ITPP 0.1 M or the vehicle. The eﬀect of ITPP was ana-
lyzed on the tumoral growth and vascularization, and appearance of
hemorrhages within the tumor.2.6. Histological procedures
Tissues were ﬁxed overnight in 4% paraformaldehyde at 4 C, dehy-
drated in graded alcohol, cleared in xylene, embedded in paraﬃn, and
cut into 7 lm-thick sections. Chick blood vessels were labeled with bio-
tinylated Sambucus Nigra lectin (SNA-lectin) (1:1000; Vector, Burlin-
game, CA), with routine signal ampliﬁcation by ABC Elite (Vector,
Burlingame, CA) and diaminobenzidine as chromogen. For quantiﬁca-
tion of vascular density within the U87 cell nodules, three ﬁelds per
section of three diﬀerent sections were analysed for each nodule as fol-
lows: images of SNA-lectin-labeled nodules were taken with a Cool-
snap digital camera (Roper Scientiﬁc, Trenton, NJ), binarized with a
threshold determined manually for each image, and quantiﬁed for
the number of colored pixels with the IPLab software (IPLab, Scana-
lytics).
2.7. Statistical analysis
For manual and automatic quantiﬁcation of vascular parameters of
the CAM, a non parametric test of Mann and Whitney was used.3. Results
3.1. Eﬀects of ITPP on the CAM
ITPP at 0.1 M provoked obvious alterations of the CAM
vascular tree as soon as after 24 h of treatment. Compared
to the controls (Fig. 2A, C), the vascular network appeared
disorganized (Fig. 2B, D) as observed on angiographic pic-
tures, notably at the level of the microvascular bed (Fig. 2D
vs C).
We evaluated these defects by measuring several parameters
of the vascular network with the program described in Section
2, which allows an automated quantiﬁcation. Thirteen CAM
from two series of experiments were analyzed. A treatment
with ITPP led to a signiﬁcant decrease in parameters such as
Fig. 2. ITPP defects on CAM vasculature. (A and B) Low magniﬁ-
cation angiographic images of CAMs treated with the vehicle (A) or
ITPP 0.1 M (B). (C and D) Higher magniﬁcations of the insets of A
and B respectively. Scale bars: 2 mm (A and B) and 400 lm (C and D).
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number of bifurcations (23%, P < 0.01) and total length of
the vascular tree (22%, P < 0.002) (Fig. 3A–D). The number
of SOV was also lowered, although not signiﬁcantly (7%,
P = 0.1) (Fig. 3E).
3.2. Eﬀects on experimental glioma
Following an experimental model described previously [20],
nodules grown from U87 cells grafted onto the CAM at
embryonic day 10 (E10) started to be invaded in their periph-
ery by CAM vessels from E12 onward (onset of treatment). InFig. 3. Quantiﬁcation of ITPP defects on CAM vasculature. Computed quan
ratio (VBR) (B), number of bifurcations (C), total length of the vascular
means ± S.E.M. *P = 0.03; **P = 0.01; ***P < 0.002.seven out of eight control nodules (two series of experiments
pooled), a large intra-nodular cavity ﬁlled with blood devel-
oped between E12 and E14 (Fig. 4). In nodules treated with
ITPP 0.1 M, these hemorrhages were reduced both in terms
of incidence (6 out of 11 nodules) and intensity (Fig. 4).
3.3. ITPP decreased nodule invasion by CAM vessels
Histological analysis was performed on two control and four
ITPP-treated nodules. Sections of E14 (2 days of treatment)
control nodules showed a highly necrotic core, while the area
at the frontline with the CAM was rich in blood vessels of
chick origin, as revealed by labeling with SNA-lectin
(Fig. 5A). In ITPP-treated nodules, a necrotic core and a vas-
cularized area were also visible (Fig. 5B, C). However, mea-
surements of vascular density in the vascularized area (see
speciﬁc characteristics of this quantiﬁcation in Section 2) re-
vealed a signiﬁcant decrease in ITPP-treated glioma (Fig. 5E,
F) compared to controls (Fig. 5D) (28.37 ± 0.77 vs
23.85 ± 0.83, P < 0.002; 3 ITPP-treated and two control nod-
ules were analyzed). Thickness of this area also appeared re-
duced (Fig. 5A vs B, C).4. Discussion
ITPP has been synthesized as a derivative of IP6 with in-
creased membrane permeability and the ability to lower Hb
aﬃnity for oxygen on free Hb as well as on whole blood [7].
Since pO2 is an important regulator of angiogenesis, we
hypothesized that, by facilitating oxygen availability at physi-
ological pO2 values, ITPP could act as an anti-angiogenic com-
pound.
In the CAMmodel, ITPP triggered an apparent disorganiza-
tion and a decreased vascular density of the vasculature, as ob-tiﬁcation of number of ﬁrst order vessels (FOV) (A), vessel/background
tree (D) and number of second order vessels (SOV) (E). Values are
Fig. 4. Eﬀects of ITPP on the development of experimental U87
glioma. U87 cells growing as nodules on CAM treated with vehicle (A,
B, E, F) or ITPP 0.1 M (C, D, G, H). (A–D) nodules at E12 (beginning
of the treatment). (E–F) same nodules at E14. Hem: hemorrhages.
Scale bar: 2 mm.
Fig. 5. Histochemical analysis of experimental U87 glioma at E14
after treatment with ITPP. (A–C) transversal sections of a control
nodule (A) and two ITPP-treated nodules with strong (B) or moderate
(C) responses to treatment, labeled with Sambucus Nigra lectin; arrows
point the CAM. (D–F) higher magniﬁcations of the insets of A–C
respectively. VA, vascularized area; NA, necrotic area; HC, hemor-
rhagic cavity. Scale bars: 250 lm (A–C) and 100 lm (D–F).
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consistent with an anti-angiogenic eﬀect. In order to assess
the signiﬁcance and reproducibility of the eﬀect, architectural
parameters of the vascular tree were quantiﬁed. Such quantiﬁ-
cation required automated tools as manual quantiﬁcation is
time-consuming and prone to subjectivity. However, few of
the automated methods currently described allow a real auto-
matic and exhaustive description of the vascular network. For
this purpose, we developed a computer-based program allow-
ing an easy and fast quantiﬁcation on large series of images, of
several parameters relevant to describe the morphology of the
CAM vasculature. The program proved reliable, as: (i) it pro-
vided a full intra-assay reproducibility while manual quantiﬁ-
cation displayed both intra- and inter-observer variability
(data not shown), and (ii) plots of the automated against the
manual results for the ‘‘number of FOV’’ showed linear regres-
sion curves with high correlation scores. All parameters com-
puted by the program were aﬀected, notably concerning the
total vessel length, the VBR (which reﬂects the vascular den-
sity), the number of bifurcations and the number of FOV.
The number of SOV was less aﬀected than the other parame-
ters, which may reﬂect the heterogeneity of the vascular tree:
the SOV, which correspond to larger and more mature vessels
than FOV, may be less prone to remodeling and for this reason
less sensitive to the action of ITPP.
The eﬀects observed on the development of experimental tu-
mors grafted onto the CAM were also indicative of anti-angio-
genic properties of ITPP. This experimental tumor, in presence
of the control solution, showed blood vessel development from
E12 and the appearance of necrotic area and hemorrhages atlater stages. As early as after 2 days of ITPP treatment, the size
of nodules was reduced and less hemorrhages occurred. In
addition, there was a decrease in the vascularized area and a
reduction in the number of neovessels. These data suggest that
ITPP may serve as an anti-tumoral compound, notably acting
via inhibition of angiogenesis. In support of this hypothesis,
ITPP had no eﬀect on U87 cell proliferation in vitro (assessed
by both [3H]-thymidine incorporation and MTT assays, data
not shown) at concentrations up to at least 0.01 M.
The mechanisms by which ITPP may interfere with angio-
genesis remain to be determined. Our hypothesis was that
ITPP could counteract hypoxia-induced angiogenesis. In sup-
port of this hypothesis, capillary tube formation by endothelial
cells is speciﬁcally inhibited in vitro in presence of ITPP-loaded
red blood cells made thus capable to release higher amounts of
O2, while ITPP alone has no eﬀect [11]. In addition, ITPP has
no eﬀect on endothelial cell proliferation in vitro (see annexe).
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sible for the eﬀects of ITPP, notably on the physiological neo-
angiogenesis of the CAM, studied under room atmosphere
(pO2 around 150 Torr) while ITPP as well as IP6 are active
on haemoglobin for pO2 values up to 125 Torr [7]. Therefore,
other mechanisms of action have to be considered. ITPP ac-
tions may be converted intracellularly into IP6 or other bioac-
tive phosphatidylinositols, as it has been shown for IP6 itself
[5]. In addition, anti-angiogenic properties of IP6 have been re-
ported [21]. However, no data are currently available about
ITPP metabolism in vivo. It appears that, when considering
the inhibition of angiogenesis by ITPP two main mechanisms
should be considered: (1) an indirect one, when ITPP is taken
up by RBCs and thus lowers the aﬃnity of hemoglobin for O2,
leading to delivery of higher oxygen amounts under hypoxia,
and (2) a direct mechanism, following the uptake of ITPP by
cells and its subsequent metabolism within those cells.
Doses used for ITPP treatments were high: 2.5 lmoles ap-
plied on a 1 cm2-surface for the treatments on the CAM and
U87 cell nodules. No signiﬁcant eﬀect of ITPP was observed
in the CAM assay with three time-lower doses (0.8 lmoles)
(data not shown). Requirement of such high doses for the ef-
fect to occur may be explained if the main mechanism of action
was via the allosteric regulation of oxygen delivery by the
RBCs, which would require ITPP to cross the plasma mem-
branes of these cells. Although its membrane permeability is
higher than IP6, ITPP still remains a polar molecule displaying
six negative charges. More permeant compounds with ITPP
properties might be interesting to investigate in this respect.
Even at the high doses, ITPP did not appear to be toxic for
the chick embryo, which is in accordance with the lack of tox-
icity observed on cell cultures in vitro and in mice in vivo
(unpublished data). Similarly, IP6 has also been described as
non toxic when administered to animals [22,23] and humans
[24,25].
In conclusion, we suggest that ITPP may be a compound of
interest for anti-cancer strategies, considering its anti-angio-
genic properties. Although the mechanisms of action of ITPP
are not fully understood, its ability to minimize or remove hy-
poxia points out to a novel approach for regulating angiogenic
processes.
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